Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.76 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | C1R | P00736 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423802 | 0.86 | DPP4 (1.00) | DPP4DPP8CYP3A4CYP2C19KCNH2 | |
| SCHEMBL4421292 | 0.86 | DPP4 (0.73) | DPP4DPP8CYP3A4CYP2C19KCNH2 | |
| SCHEMBL6223323 | 0.84 | DPP4 (0.55) | DPP4DPP8CYP3A4 | |
| SCHEMBL6220647 | 0.80 | DPP4 (0.59) | DPP4TLR8L3MBTL1MAPK1TDP1 | |
| SCHEMBL4422172 | 0.79 | DPP4 (0.67) | DPP4CYP3A4GUSBTLR8L3MBTL1 | |
| SCHEMBL4421301 | 0.79 | DPP4 (0.56) | DPP4CYP3A4CYP2C19C1RTLR8 | |
| SCHEMBL19856451 | 0.77 | MAOA (0.56) | BCHECYP3A4CYP2C19KCNH2GUSB | |
| SCHEMBL6072338 | 0.77 | KDM4E (0.62) | DPP4L3MBTL1HSD17B10 | |
| SCHEMBL6223940 | 0.74 | DPP4 (0.48) | DPP4DPP8L3MBTL1TDP1 | |
| SCHEMBL4419602 | 0.73 | DPP4 (0.56) | DPP4TLR8CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4216197-B2 | — | — | 2009-01-28 | — | — | JP | claimed |
| EP-1476429-B1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | claimed |
| JP-2005526034-A | — | — | 2005-09-02 | — | — | JP | claimed |
| EP-1476429-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | claimed |
| US-6800650-B2 | FOR THERAPY AND PROPHYLAXIS OF DIABETES, PARTICULARLY NON-INSULIN DEPENDENT DIABETES MELLITUS AND IMPAIRED GLUCOSE TOLERANCE. | HOFFMANN-LA ROCHE INC. | 2004-10-05 | — | — | US | claimed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | claimed |
| WO-2003068748-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | claimed |
| EP-1476429-B1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1476429-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2003068748-A9 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-6800650-B2 | FOR THERAPY AND PROPHYLAXIS OF DIABETES, PARTICULARLY NON-INSULIN DEPENDENT DIABETES MELLITUS AND IMPAIRED GLUCOSE TOLERANCE. | HOFFMANN-LA ROCHE INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | disclosed |
| WO-2003068748-A1 | NOVEL PYRIDINE- AND QUINOLINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195188-A1 | Pyridine and quinoline derivatives | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 10/4885BCHE 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.